Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome.
17 publications have been identified in PubMed for primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome. Research spans Review / Meta-Analysis (35%), Case Report / Case Series (29%), and Epidemiology / Natural History (24%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 5 | 29% |
Disease patterns and progression | 4 | 24% |
Testing and diagnosis research | 1 | 6% |
New treatment approaches | 1 | 6% |
Uhlenbusch N (2026). [PMID: 41623132](https://pubmed.ncbi.nlm.nih.gov/41623132/). *Liver international : official journal of the International Association for the Study of the Liver*. [Review / Meta-Analysis]
Tan JJ (2026). [PMID: 42043878](https://pubmed.ncbi.nlm.nih.gov/42043878/). *Hepatol Commun*. [Review / Meta-Analysis]
Guo T (2026). [PMID: 41879927](https://pubmed.ncbi.nlm.nih.gov/41879927/). *Int J Clin Pharm*. [Diagnostic / Biomarker]
Zhang Z (2026). [PMID: 42148062](https://pubmed.ncbi.nlm.nih.gov/42148062/). *Front Immunol*. [Review / Meta-Analysis]
Al Alwan A (2026). [PMID: 41637192](https://pubmed.ncbi.nlm.nih.gov/41637192/). *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association*. [Case Report / Case Series]
Sohal A (2025). [PMID: 40337770](https://pubmed.ncbi.nlm.nih.gov/40337770/). *Translational gastroenterology and hepatology*. [Epidemiology / Natural History]
Lei X (2025). [PMID: 40760529](https://pubmed.ncbi.nlm.nih.gov/40760529/). *Medicine*. [Case Report / Case Series]
Filho RCS (2025). [PMID: 40527803](https://pubmed.ncbi.nlm.nih.gov/40527803/). *Medicine*. [Epidemiology / Natural History]
Filipovic B (2025). [PMID: 40076490](https://pubmed.ncbi.nlm.nih.gov/40076490/). *International journal of molecular sciences*. [Review / Meta-Analysis]
Hassen H (2025). [PMID: 41355485](https://pubmed.ncbi.nlm.nih.gov/41355485/). *Future science OA*. [Case Report / Case Series]